Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Takeda's inflammatory bowel disease drug

FDA panel backs Takeda's inflammatory bowel disease drug

FDA panel backs Takeda's inflammatory bowel disease drug. Vedolizumab on course for US approval to treat Crohn's disease and ulcerative colitis. ... Takeda's Millennium Pharmaceuticals unit took a step closer to US approval for one of its top pipeline

Latest news

  • FDA grants priority review to Takeda's colitis drug FDA grants priority review to Takeda's colitis drug

    FDA grants priority review to Takeda's colitis drug. Accelerates review time for vedolizumab. ... One of Takeda's top pipeline prospects - vedolizumab for ulcerative colitis ( UC) - has been given a priority review by the US Food and Drug Administration (

  • Phase III data raise hopes for Takeda's <b>vedolizumab</b> Phase III data raise hopes for Takeda's vedolizumab

    Phase III data raise hopes for Takeda's vedolizumab. Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease. ... Data from phase III trials of Takeda's inflammatory bowel disease ( IBD) drug vedolizumab suggests the company's

  • Takeda files IBD drug <b>vedolizumab</b> in Europe Takeda files IBD drug vedolizumab in Europe

    Takeda files IBD drug vedolizumab in Europe. Potential safer alternative to TNF blockers like Remicade and Humira. ... Takeda has filed for approval in Europe of inflammatory bowel disease ( IBD) drug vedolizumab, one of its key pipeline drugs.

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    The CHMP also gave the nod to Takeda's locally-targeted drug for ulcerative colitis and Crohn's disease - Entyvio ( vedolizumab). ... Vedolizumab's regulatory review in the US has been delayed by a few months, but has been backed by an FDA advisory

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    There has also been a delay in the US for regulatory review of its new ulcerative colitis candidate vedolizumab although it remains on track for Crohn's disease.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel ( TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel ( TAK-700),

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Spoonful of Sugar

Spoonful of Sugar (SoS) is a unique and diverse team of specialists in illness and medicines-related behaviour, hand-picked from academic,...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....